Antibiotic resistance in K. pneumoniae: perspectives, challenges, health risks, therapeutic approaches
Frontiers in Microbiology · 17.08.2026 · 17
DOI: 10.3389/fmicb.2026.1816741 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 17.08.2026. Verfasst von Tülay Kandemir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Research and Application Center, Cukurova University, Adana, Türkiye. Die Arbeit nennt 298 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Klebsiella pneumoniae is an opportunistic Gram-negative pathogen of increasing global concern due to its expanding virulence potential and rapid acquisition of antimicrobial resistance. Traditionally associated with hospital-acquired infections such as pneumonia, urinary tract infections, and bloodstream infections, K. pneumoniae has evolved into a highly diverse species comprising classical (cKP), hypervirulent (hvKP), multidrug-resistant (MDR), and emerging carbapenem-resistant hypervirulent (CR-hvKP) variants. Its pathogenicity is driven by a wide array of virulence factors, including capsular polysaccharides, siderophores, fimbriae, lipopolysaccharides, and multiple secretion systems, all of which facilitate immune evasion, tissue invasion, biofilm formation, and environmental survival. Parallel to this, K. pneumoniae has developed extensive resistance through intrinsic mechanisms, such as efflux pumps and porin alterations, as well as acquired determinants including ESBLs, carbapenemases (KPC, NDM, and OXA-48), 16S rRNA methyltransferases, and plasmid-mediated mcr genes conferring colistin resistance. These combined traits have led to widespread dissemination of MDR and XDR strains, limiting therapeutic options and contributing to significant morbidity, mortality, and healthcare burdens worldwide. Epidemiologically, resistance hotspots have emerged in Asia, Europe, and the Middle East, while hvKP continues to expand beyond its original endemic regions. Diagnostic challenges, therapeutic limitations, and economic pressures further complicate clinical management. This review synthesizes current knowledge on K. pneumoniae virulence mechanisms, resistance evolution, epidemiology, and clinical impact, and highlights emerging therapeutic strategies aimed at overcoming this escalating public health threat.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biotechnology Research and Application Center, Cukurova University, Adana, Türkiye.
- Faculty of Pharmacy, Çukurova University, Adana, Türkiye.
- Department of Nutrition and Dietetics, Acibadem Mehmet Ali Aydinlar University, Istanbul, Türkiye.
- Department of Nutrition and Dietetics, Gazi University, Ankara, Türkiye.
- Institute of Basics of Health Sciences, Midwifery and Health Visiting, Faculty of Health Sciences, University of Pécs, Pécs, Hungary.
- Department of Seafood Processing Technology, Faculty of Fisheries, Cukurova University, Adana, Türkiye.
Zitieren
APA
Kandemir, T., Bagheri, S. E., Ayakdaş, G., Ağagündüz, D., Raposa, B., & Ozogul, F. (2026). Antibiotic resistance in K. pneumoniae: perspectives, challenges, health risks, therapeutic approaches. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1816741
Vancouver
Kandemir T, Bagheri SE, Ayakdaş G, Ağagündüz D, Raposa B, Ozogul F. Antibiotic resistance in K. pneumoniae: perspectives, challenges, health risks, therapeutic approaches. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1816741
BibTeX
@article{Kandemir2026,
author = {Kandemir, Tülay and Bagheri, Shiva Eivazi and Ayakdaş, Gamze and Ağagündüz, Duygu and Raposa, Bence and Ozogul, Fatih},
title = {Antibiotic resistance in K. pneumoniae: perspectives, challenges, health risks, therapeutic approaches},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1816741}
}
EUVIMED